Recursion Pharmaceuticals, Inc. (RXRX) Misses Q3 EPS by 4c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $10.53 million versus the consensus estimate of $11.24 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Delta Air shares slip despite strong outlook, Melius says
• Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP